Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients With Atrial Fibrillation

NCT04571385 is registered in ClinicalTrials.gov with Acesion Pharma as lead sponsor.

NCT NCT04571385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04571385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients With Atrial Fibrillation
Lead sponsor
Acesion Pharma
Phase
Phase 2
Overall status
Completed
Start date
September 9, 2019
Completion date
January 23, 2023
Enrollment
66 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation